Importantly, high HIF-1α levels and, to some extent, high Gal3 expression are associated with a poorer survival of human cancer patients, in particular in association with mutant KRAS, which emphasizes the need for suitable potent inhibitors (Figure S4C–F). This evidence concerns the gene LGALS3 and cancer.